Drug Trial Radar · NCT05783323
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
13
Planned (sponsor's estimate)
Start
Feb 14, 2024
Primary completion
Oct 1, 2028
Study completion Oct 1, 2030
Sponsor
- Lead sponsor
- Children's Hospital of PhiladelphiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bayer
- First posted
- Mar 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Conditions
- Differentiated Thyroid Cancer
- Pediatric Cancer
- Cancer
- Cancer, Thyroid
Interventions
Larotrectinib monotherapyDrug
Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
131I therapyRadiation
Patients will receive 131I therapy after 6 months of larotrectinib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with complete pulmonary structural responseTime frame: 18 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.